The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Forced Expiratory Volume

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Forced Expiratory Volume

 

Psychiatry related information on Forced Expiratory Volume

 

High impact information on Forced Expiratory Volume

  • RESULTS: The patients treated with inhaled tobramycin had an average increase in forced expiratory volume in one second (FEV1) of 10 percent at week 20 as compared with week 0, whereas the patients receiving placebo had a 2 percent decline in FEV1 (P<0.001) [9].
  • Bronchial sensitivity to methacholine (the concentration provoking a 20 percent decrease in the forced expiratory volume in one second [PC20]) was measured twice yearly [10].
  • As compared with treatment with high-dose budesonide, treatment with low-dose budesonide plus theophylline resulted in greater improvements in forced vital capacity (P=0.03) and forced expiratory volume in one second (P= 0.03) [11].
  • Serum total IgE levels were strongly correlated (r = 0.65, P < 0.01) in pairs of siblings concordant for bronchial hyperresponsiveness (defined as a > or = 20 percent decrease in the forced expiratory volume in one second produced by histamine [threshold dose, < or = 16 mg per milliliter]), suggesting that these traits are coinherited [12].
  • Measurements of the forced expiratory volume in one second, performed hourly for 12 consecutive hours, showed that a single dose of salmeterol produced a greater mean area under the curve than two doses of albuterol taken 6 hours apart (6.3 vs. 4.9 liter.hr, P < 0.05) [13].
 

Chemical compound and disease context of Forced Expiratory Volume

 

Biological context of Forced Expiratory Volume

 

Anatomical context of Forced Expiratory Volume

 

Associations of Forced Expiratory Volume with chemical compounds

 

Gene context of Forced Expiratory Volume

  • METHODS: We studied nine nonsmoking healthy subjects, 20 nonsmoking patients with asthma, 10 nonatopic smoking patients with CB (forced expiratory volume in 1 second: 98.4% +/- 11.3%) and 17 patients with COPD (forced expiratory volume in 1 second: 51.2% +/- 14.3%) [34].
  • However, in the children, the GSTP1 val(105)/val(105) and GSTM1 null genotypes were associated with significantly higher forced expiratory volume in 1 s (FEV(1)) and FVC values as percentage of predicted [35].
  • When comparing 31 G85E/F508del and F508del/F508del patients, there were no differences in median age at diagnosis, mean sweat chloride value, most recent weight for height, most recent forced expiratory volume in one second % predicted, prevalence of chronic Pseudomonas aeruginosa colonisation and typical CF complications [36].
  • In all LTx patients, MMP-9 and the MMP-9:TIMP-1 ratio were negatively correlated with forced expiratory volume in 1 second values (rho = -0.47, p = 0.01, and rho = -0.53, p = 0.003, respectively) [37].
  • On the screening day and during the study periods, increasing concentrations of NKA (3.3 x 10(-9) to 1.0 x 10(-6) mol x mL(-1)) were inhaled, until the forced expiratory volume in one second (FEV1) and specific airway conductance (sGaw) decreased by at least 20 and 50%, respectively [38].
 

Analytical, diagnostic and therapeutic context of Forced Expiratory Volume

References

  1. Moderate alcohol dose and chronic obstructive pulmonary disease: not a cause of hypoventilation. Sahn, S.A., Scoggin, C.H., Chernow, B. Arch. Intern. Med. (1979) [Pubmed]
  2. Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with mild chronic obstructive pulmonary disease. Light, R.W., Chetty, K.G., Stansbury, D.W. Am. J. Med. (1983) [Pubmed]
  3. Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Kanazawa, H., Asai, K., Hirata, K., Yoshikawa, J. Am. J. Med. (2003) [Pubmed]
  4. Persistence and new onset of asthma and chronic bronchitis evaluated longitudinally in a community population sample of adults. Postma, D.S., Lebowitz, M.D. Arch. Intern. Med. (1995) [Pubmed]
  5. Changes in pulmonary mechanics with increasing disease severity in children and young adults with cystic fibrosis. Hart, N., Polkey, M.I., Clément, A., Boulé, M., Moxham, J., Lofaso, F., Fauroux, B. Am. J. Respir. Crit. Care Med. (2002) [Pubmed]
  6. Use of peak flow variability and methacholine responsiveness in predicting changes from pre-test diagnosis of asthma. Parameswaran, K., Belda, J., Sears, M.R. Eur. Respir. J. (1999) [Pubmed]
  7. Smoking reduction and the rate of decline in FEV(1): results from the Lung Health Study. Simmons, M.S., Connett, J.E., Nides, M.A., Lindgren, P.G., Kleerup, E.C., Murray, R.P., Bjornson, W.M., Tashkin, D.P. Eur. Respir. J. (2005) [Pubmed]
  8. The socioeconomic position of employed women, risk factors and mortality. Heslop, P., Smith, G.D., Macleod, J., Hart, C. Social science & medicine (1982) (2001) [Pubmed]
  9. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. Ramsey, B.W., Pepe, M.S., Quan, J.M., Otto, K.L., Montgomery, A.B., Williams-Warren, J., Vasiljev-K, M., Borowitz, D., Bowman, C.M., Marshall, B.C., Marshall, S., Smith, A.L. N. Engl. J. Med. (1999) [Pubmed]
  10. A controlled trial of immunotherapy for asthma in allergic children. Adkinson, N.F., Eggleston, P.A., Eney, D., Goldstein, E.O., Schuberth, K.C., Bacon, J.R., Hamilton, R.G., Weiss, M.E., Arshad, H., Meinert, C.L., Tonascia, J., Wheeler, B. N. Engl. J. Med. (1997) [Pubmed]
  11. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. Evans, D.J., Taylor, D.A., Zetterstrom, O., Chung, K.F., O'Connor, B.J., Barnes, P.J. N. Engl. J. Med. (1997) [Pubmed]
  12. Genetic susceptibility to asthma--bronchial hyperresponsiveness coinherited with a major gene for atopy. Postma, D.S., Bleecker, E.R., Amelung, P.J., Holroyd, K.J., Xu, J., Panhuysen, C.I., Meyers, D.A., Levitt, R.C. N. Engl. J. Med. (1995) [Pubmed]
  13. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. Pearlman, D.S., Chervinsky, P., LaForce, C., Seltzer, J.M., Southern, D.L., Kemp, J.P., Dockhorn, R.J., Grossman, J., Liddle, R.F., Yancey, S.W. N. Engl. J. Med. (1992) [Pubmed]
  14. Decreased peroxynitrite inhibitory activity in induced sputum in patients with bronchial asthma. Kanazawa, H., Shiraishi, S., Hirata, K., Yoshikawa, J. Thorax (2002) [Pubmed]
  15. Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients. Truyen, E., Coteur, L., Dilissen, E., Overbergh, L., Dupont, L.J., Ceuppens, J.L., Bullens, D.M. Thorax (2006) [Pubmed]
  16. Effect of oral salbutamol and slow-release aminophylline on exercise tolerance in chronic bronchitis. Leitch, A.G., Morgan, A., Ellis, D.A., Bell, G., Haslett, C., McHardy, G.J. Thorax (1981) [Pubmed]
  17. Emerging clinical picture of lymphangioleiomyomatosis. Cohen, M.M., Pollock-BarZiv, S., Johnson, S.R. Thorax (2005) [Pubmed]
  18. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. McKay, S.E., Howie, C.A., Thomson, A.H., Whiting, B., Addis, G.J. Thorax (1993) [Pubmed]
  19. Long-term metaproterenol therapy in asthmatic children. Brandon, M.L. JAMA (1976) [Pubmed]
  20. Bronchial biopsy evidence for leukocyte infiltration and upregulation of leukocyte-endothelial cell adhesion molecules 6 hours after local allergen challenge of sensitized asthmatic airways. Montefort, S., Gratziou, C., Goulding, D., Polosa, R., Haskard, D.O., Howarth, P.H., Holgate, S.T., Carroll, M.P. J. Clin. Invest. (1994) [Pubmed]
  21. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Stein, R.T., Sherrill, D., Morgan, W.J., Holberg, C.J., Halonen, M., Taussig, L.M., Wright, A.L., Martinez, F.D. Lancet (1999) [Pubmed]
  22. Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes. Phillips, A., Shaper, A.G., Whincup, P.H. Lancet (1989) [Pubmed]
  23. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Wong, C.S., Pavord, I.D., Williams, J., Britton, J.R., Tattersfield, A.E. Lancet (1990) [Pubmed]
  24. Leukocyte activation in allergen-induced late-phase asthmatic reactions. Durham, S.R., Carroll, M., Walsh, G.M., Kay, A.B. N. Engl. J. Med. (1984) [Pubmed]
  25. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid. Saleh, D., Ernst, P., Lim, S., Barnes, P.J., Giaid, A. FASEB J. (1998) [Pubmed]
  26. Inflation of antishock trousers increases bronchial response to methacholine in healthy subjects. Regnard, J., Baudrillard, P., Salah, B., Dinh Xuan, A.T., Cabanes, L., Lockhart, A. J. Appl. Physiol. (1990) [Pubmed]
  27. Respiratory muscle activity in the assessment of bronchial responsiveness in asthmatic children. Sprikkelman, A.B., Van Eykern, L.A., Lourens, M.S., Heymans, H.S., Van Aalderen, W.M. J. Appl. Physiol. (1998) [Pubmed]
  28. Bronchoalveolar lavage fluid obtained from smokers exhibits increased monocyte chemokinetic activity. Koyama, S., Rennard, S.I., Daughton, D., Shoji, S., Robbins, R.A. J. Appl. Physiol. (1991) [Pubmed]
  29. Chronic cough as the sole presenting manifestation of bronchial asthma. Corrao, W.M., Braman, S.S., Irwin, R.S. N. Engl. J. Med. (1979) [Pubmed]
  30. The bronchodilator effects and pharmacokinetics of caffeine in asthma. Becker, A.B., Simons, K.J., Gillespie, C.A., Simons, F.E. N. Engl. J. Med. (1984) [Pubmed]
  31. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. Israel, E., Dermarkarian, R., Rosenberg, M., Sperling, R., Taylor, G., Rubin, P., Drazen, J.M. N. Engl. J. Med. (1990) [Pubmed]
  32. Periodic treatment regimens with inhaled steroids in asthma or chronic obstructive pulmonary disease. Is it possible? van Schayck, C.P., van den Broek, P.J., den Otter, J.J., van Herwaarden, C.L., Molema, J., van Weel, C. JAMA (1995) [Pubmed]
  33. Cromolyn therapy in patients with bronchial asthma. Effect on inhalation challenge with allergen, histamine, and methacholine. Ryo, U.Y., Kang, B., Townley, R.G. JAMA (1976) [Pubmed]
  34. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. Lacoste, J.Y., Bousquet, J., Chanez, P., Van Vyve, T., Simony-Lafontaine, J., Lequeu, N., Vic, P., Enander, I., Godard, P., Michel, F.B. J. Allergy Clin. Immunol. (1993) [Pubmed]
  35. Effects of glutathione S-transferase M1, T1 and P1 on lung function in asthmatic families. Carroll, W.D., Lenney, W., Jones, P.W., Strange, R.C., Child, F., Whyte, M.K., Primhak, R.A., Fryer, A.A. Clin. Exp. Allergy (2005) [Pubmed]
  36. Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients. Decaestecker, K., Decaestecker, E., Castellani, C., Jaspers, M., Cuppens, H., De Boeck, K. Eur. Respir. J. (2004) [Pubmed]
  37. Sputum levels of metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, and their ratio correlate with airway obstruction in lung transplant recipients: relation to tumor necrosis factor-alpha and interleukin-10. Beeh, K.M., Beier, J., Kornmann, O., Micke, P., Buhl, R. J. Heart Lung Transplant. (2001) [Pubmed]
  38. The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics. Van Schoor, J., Joos, G.F., Chasson, B.L., Brouard, R.J., Pauwels, R.A. Eur. Respir. J. (1998) [Pubmed]
  39. The value of maintenance theophylline in steroid-dependent asthma. Nassif, E.G., Weinberger, M., Thompson, R., Huntley, W. N. Engl. J. Med. (1981) [Pubmed]
  40. Airways responsiveness and development and remission of chronic respiratory symptoms in adults. Xu, X., Rijcken, B., Schouten, J.P., Weiss, S.T. Lancet (1997) [Pubmed]
  41. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. Rodrigo, G., Rodrigo, C., Burschtin, O. Am. J. Med. (1999) [Pubmed]
  42. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Dahl, M., Tybjaerg-Hansen, A., Vestbo, J., Lange, P., Nordestgaard, B.G. Am. J. Respir. Crit. Care Med. (2001) [Pubmed]
  43. Effect of methacholine induced bronchoconstriction on the pulmonary distribution and plasma pharmacokinetics of inhaled sodium cromoglycate in subjects with normal and hyperreactive airways. Richards, R., Haas, A., Simpson, S., Britten, A., Renwick, A., Holgate, S. Thorax (1988) [Pubmed]
 
WikiGenes - Universities